Nurix Therapeutics shares tumble 9% on wider-than-expected Q3 loss, revenue miss
NegativeFinancial Markets
Nurix Therapeutics has faced a significant setback as its shares dropped by 9% following a wider-than-expected loss in the third quarter and a revenue miss. This decline highlights the challenges the company is facing in the competitive biotech landscape, raising concerns among investors about its future performance and financial health.
— Curated by the World Pulse Now AI Editorial System